Serotonergic pharmacology in animal models: From behavioral disorders to dyskinesia

Neuropharmacology

Volumn 81, Issue , 2014, Pages 15-30

  Beaudoin Gobert, Maude ^a,b   Sgambato Faure, Véronique ^a,b  

^a INSTITUT DES SCIENCES COGNITIVES   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Aggressiveness; Anorexia; Anxiety; Depression; Dyskinesia; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3 DIHYDRO 3 ISOPROPYL 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; BEFLOXATONE; BUSPIRONE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LINEZOLID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL BEHAVIOR; ANOREXIA; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; DEPRESSION; DISEASE MODEL; DRUG SELECTIVITY; DRUG TARGETING; DYSKINESIA; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PRIMATE; PRIORITY JOURNAL; RODENT; VALIDITY; ANIMAL; BEHAVIOR; DRUG THERAPY; DYSKINESIAS; GENETICS; HUMAN; METABOLISM;

ANIMALS; BEHAVIORAL SYMPTOMS; DISEASE MODELS, ANIMAL; DYSKINESIAS; HUMANS; SEROTONIN; SEROTONIN AGENTS;

EID: 84894150676     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.01.031     Document Type: Review

References (225)

1. J.K. Abrams, P.L. Johnson, J.H. Hollis, and C.A. Lowry Anatomic and functional topography of the dorsal raphe nucleus Ann. N. Y. Acad. Sci. 1018 2004 46 57
2. B. Alexander, J. Warner-Schmidt, T.M. Eriksson, C. Tamminga, M. Arango-Lievano, S. Ghose, M. Vernov, M. Stavarache, S. Musatov, M. Flajolet, P. Svenningsson, P. Greengard, and M.G. Kaplitt Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens Sci. Transl. Med. 2 2010 54ra76
3. M. Altemus, J.R. Glowa, E. Galliven, Y.M. Leong, and D.L. Murphy Effects of serotonergic agents on food-restriction-induced hyperactivity Pharmacol. Biochem. Behav. 53 1996 123 131
4. L. Asarian, B.S. Kopf, N. Geary, and W. Langhans Pharmacological, but not genetic, disruptions in 5-HT2C subreceptor function attenuate LPS anorexia in mice Pharmacol. Biochem. Behav. 86 2007 493 498
5. Y. Aubert, M.A. Bohl, J.R. Lange, N.R. Diol, K.A. Allers, B. Sommer, N.A. Datson, and D.H. Abbott Chronic systemic administration of serotonergic ligands flibanserin and 8-OH-DPAT enhance HPA axis responses to restraint in female marmosets Psychoneuroendocrinology 38 2012 145 154
6. Y. Aubert, M.L. Gustison, L.A. Gardner, M.A. Bohl, J.R. Lange, K.A. Allers, B. Sommer, N.A. Datson, and D.H. Abbott Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality J. Sex. Med. 9 2012 694 707
7. E.C. Azmitia, and M. Segal An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat J. Comp. Neurol. 179 1978 641 667
8. U.F. Bailer, G.K. Frank, S.E. Henry, J.C. Price, C.C. Meltzer, C.A. Mathis, A. Wagner, L. Thornton, J. Hoge, S.K. Ziolko, C.R. Becker, C.W. McConaha, and W.H. Kaye Exaggerated 5-HT1A but Normal 5-HT2A receptor activity in individuals III with anorexia nervosa Biol. Psychiatry 61 2007 1090 1099
9. B. Bandelow, J. Zohar, E. Hollander, S. Kasper, and H.-J. Möller World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry 3 2002 171 199
10. M. Barrot, J.D. Olivier, L.I. Perrotti, R.J. DiLeone, O. Berton, A.J. Eisch, S. Impey, D.R. Storm, R.L. Neve, and J.C. Yin CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli Proc. Natl. Acad. Sci. 99 2002 11435 11440
11. A. Baudry, S. Mouillet-Richard, B. Schneider, J.-M. Launay, and O. Kellermann miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants Science 329 2010 1537 1541
12. BBC Ecstasy & Agony 2001 http://www.bbc.co.uk/science/horizon/2000/ ecstasyagony.shtml
13. 3H] spiperone binding Brain Res. 379 1986 294 299
14. B.A. Beisner, and L.A. Isbell Factors affecting aggression among females in captive groups of rhesus macaques (Macaca mulatta) Am. J. Primatol. 73 2011 1152 1159
15. M. Berger, J.A. Gray, and B.L. Roth The expanded biology of serotonin Annu. Rev. Med. 60 2009 355 366
16. C.L. Bethea, F.B. Lima, M.L. Centeno, K.V. Weissheimer, O. Senashova, A.P. Reddy, and J.L. Cameron Effects of citalopram on serotonin and CRF systems in the midbrain of primates with differences in stress sensitivity J. Chem. Neuroanat. 41 2011 200 218
17. C.L. Bethea, J.M. Streicher, S.J. Mirkes, R.L. Sanchez, A.P. Reddy, and J.L. Cameron Serotonin-related gene expression in female monkeys with individual sensitivity to stress Neuroscience 132 2005 151 166
18. E. Bezard, E. Tronci, E.Y. Pioli, Q. Li, G. Porras, A. Björklund, and M. Carta Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia Neurosci. Res. 77 4 2013 242 246
19. F. Bibbiani, J.D. Oh, and T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 2001 1829 1834
20. C. Bishop, J.A. George, W. Buchta, A.A. Goldenberg, M. Mohamed, S.O. Dickinson, S. Eissa, and K.L. Eskow Jaunarajs Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats Eur. J. Neurosci. 36 2012 2839 2848
21. C.R. Bjarkam, J.C. Sørensen, and F.A. Geneser Distribution and morphology of serotonin-immunoreactive neurons in the brainstem of the New Zealand white rabbit J. Comp. Neurol. 380 1997 507 519
22. P.J. Blanchet, F. Calon, M. Morissette, A. Hadj Tahar, N. Bélanger, P. Samadi, R. Grondin, L. Grégoire, L. Meltzer, T. Di Paolo, and P.J. Bédard Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms Park. Relat. Disord. 10 5 2004 297 304
23. M. Bortolato, K. Chen, S.C. Godar, G. Chen, W. Wu, I. Rebrin, M.R. Farrell, A.L. Scott, C.L. Wellman, and J.C. Shih Social deficits and perseverative behaviors, but not overt aggression, in MAO-a hypomorphic mice Neuropsychopharmacology 36 2011 2674 2688
24. M. Bortolato, S.C. Godar, M. Melis, A. Soggiu, P. Roncada, A. Casu, G. Flore, K. Chen, R. Frau, A. Urbani, M.P. Castelli, P. Devoto, and J.C. Shih NMDARs mediate the role of monoamine oxidase a in pathological aggression J. Neurosci. 32 2012 8574 8582
25. M. Bourin, M.C. Colombel, J.P. Redrobe, J. Nizard, and G.B. Baker Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages Prog. Neuropsychopharmacol. Biol. Psychiatry 22 1998 343 351
26. L. Breuillaud, C. Rossetti, E.M. Meylan, C. Mérinat, O. Halfon, P.J. Magistretti, and J.-R. Cardinaux Deletion of CREB-regulated transcription coactivator 1 induces pathological aggression, depression-related behaviors, and neuroplasticity genes dysregulation in mice Biol. Psychiatry 72 2012 528 536
27. H.G. Brunner, M. Nelen, X.O. Breakefield, H.H. Ropers, and B.A. Van Oost Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A Science 262 1993 578 580
28. C.E. Bryant, N.M. Rupniak, and S.D. Iversen Effects of different environmental enrichment devices on cage stereotypies and autoaggression in captive cynomolgus monkeys J. Med. Primatol. 17 5 1988 257 269
29. K. Buck, and B. Ferger Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats Neuroscience 159 2009 16 20
30. S. Caccia, I. Conti, G. Viganò, and S. Garattini 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat Pharmacology 33 1986 46 51
31. D. Caille, O.-E. Bergis, C. Fankhauser, A. Gardes, R. Adam, T. Charieras, A. Grosset, V. Rovei, and F.-X. Jarreau Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile J. Pharmacol. Exp. Ther. 277 1996 265 277
32. S. Caillé, L. Stinus, E.F. Espejo, P. De Deurwaerdère, U. Spampinato, and G.F. Koob Inhibition of 5-HT neurotransmission increases clonidine protective effects on naloxone-induced conditioned place aversion in morphine-dependent rats Neuropsychopharmacology 28 2002 276 283
33. S.M.J. Camus, C. Blois-Heulin, Q. Li, M. Hausberger, and E. Bezard Behavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders? PLoS ONE 8 2013 e62141
34. S.M. Camus, C. Rochais, C. Blois-Heulin, Q. Li, M. Hausberger, and E. Bezard Birth origin differentially affects depressive-like behaviours: are captive-born cynomolgus monkeys more vulnerable to depression than their wild-born counterparts? PLoS One 8 7 2013 e67711
35. J.P. Capela, H. Carmo, F. Remião, M.L. Bastos, A. Meisel, and F. Carvalho Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview Mol. Neurobiol. 39 2009 210 271
36. G.G. Carminati, N. Deriaz, and G. Bertschy Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 312 315
37. M. Carrillo, L.A. Ricci, G.A. Coppersmith, and R.H. Melloni The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies Psychopharmacology (Berl.) 205 2009 349 368
38. M. Carta, T. Carlsson, D. Kirik, and A. Björklund Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain J. Neurol. 130 2007 1819 1833
39. E.F. Carvalho-Netto, and R.L. Nunes-de-Souza Use of the elevated T-maze to study anxiety in mice Behav. Brain Res. 148 2004 119 132
40. O. Cases, I. Seif, J. Grimsby, P. Gaspar, K. Chen, S. Pournin, U. Müller, M. Aguet, C. Babinet, and J.C. Shih Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA Science 268 1995 1763 1766
41. R.C. Casper Depression and eating disorders Depress. Anxiety 8 Suppl. 1 1998 96 104
42. R.C. Casper The "drive for activity" and " restlessness" in anorexia nervosa: potential pathways J. Affect. Disord. 92 2006 99 107
43. M.A. Cenci, C.S. Lee, and A. Björklund L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
44. D.T. Chau, P.V. Rada, K. Kim, R.A. Kosloff, and B.G. Hoebel Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell Neuropsychopharmacology 36 2011 1729 1737
45. A.C. Chen, Y. Shirayama, K.H. Shin, R.L. Neve, and R.S. Duman Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect Biol. Psychiatry 49 2001 753 762
46. K. Chen, O. Cases, I. Rebrin, W. Wu, T.K. Gallaher, I. Seif, and J.C. Shih Forebrain-specific expression of monoamine oxidase a reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase a-deficient mice J. Biol. Chem. 282 2006 115 123
47. A. Cipriani, T.A. Furukawa, G. Salanti, J.R. Geddes, J.P. Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I.M. Omori, H. McGuire, M. Tansella, and C. Barbui Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
48. A. Cipriani, M. Purgato, T.A. Furukawa, C. Trespidi, G. Imperadore, A. Signoretti, R. Churchill, N. Watanabe, and C. Barbui Citalopram versus other anti-depressive agents for depression Cochrane Database Syst. Rev. 11 2012 7
49. A.S. Clarke, M.H. Ebert, D.E. Schmidt, W.T. McKinney, and G.W. Kraemer Biogenic amine activity in response to fluoxetine and desipramine in differentially reared rhesus monkeys Biol. Psychiatry 46 1999 221 228
50. A.S. Clarke, G.W. Kraemer, and D.J. Kupfer Effects of rearing condition on HPA axis response to fluoxetine and desipramine treatment over repeated social separations in young rhesus monkeys Psychiatry Res. 79 1998 91 104
51. V. Compan Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice J. Neurosci. 24 2004 412 419
52. V. Compan, L. Laurent, A. Jean, C. Macary, J. Bockaert, and A. Dumuis Serotonin signaling in eating disorders Wiley Interdiscip. Rev. Membr. Transp. Signal 1 2012 715 729
53. G. Conductier, N. Dusticier, G. Lucas, F. Côté, G. Debonnel, A. Daszuta, A. Dumuis, A. Nieoullon, R. Hen, J. Bockaert, and others Adaptive changes in serotonin neurons of the raphe nuclei in 5-HT4 receptor knock-out mouse Eur. J. Neurosci. 24 2006 1053 1062
54. J.J. Crowley, J.A. Blendy, and I. Lucki Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test Psychopharmacology (Berl.) 183 2005 257 264
55. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci. Biobehav. Rev. 29 2005 571 625
56. P.S. D'Aquila, F. Panin, and G. Serra Long-term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test Eur. J. Pharmacol. 492 2004 61 63
57. A. Dahlström, and K. Fuxe Localization of monoamines in the lower brain stem Experientia 20 1964 398 399
58. C. Davis Eating disorders and hyperactivity: a psychobiological perspective Can. J. Psychiatry Rev. Can. Psychiatr. 42 1997 168 175
59. P. Dayan, and Q.J.M. Huys Serotonin in affective control Annu. Rev. Neurosci. 32 2009 95 126
60. L. De Angelis, and C. Furlan The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test Pharmacol. Biochem. Behav. 65 2000 649 653
61. S.F. De Boer, and J.M. Koolhaas 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis Eur. J. Pharmacol. 526 2005 125 139
62. L. De Groote, B. Olivier, and H. Westenberg Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT 1B autoreceptors: a microdialysis study in knockout mice Psychopharmacology (Berl.) 162 2002 419 424
63. L. De Groote, B. Olivier, and H.G.M. Westenberg The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice Eur. J. Pharmacol. 439 2002 93 100
64. A. Dekundy, M. Lundblad, W. Danysz, and M.A. Cenci Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav. Brain Res. 179 2007 76 89
65. C. Delaville, P.D. Deurwaerdère, and A. Benazzouz Noradrenaline and Parkinson's disease Front. Syst. Neurosci. 5 2011 31
66. D. Denys, F. de Geus, H.J.G.M. van Megen, and H.G.M. Westenberg A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors J. Clin. Psychiatry 65 2004 1040 1048
67. L. Descarries, A. Beaudet, and K.C. Watkins Serotonin nerve terminals in adult rat neocortex Brain Res. 100 1975 563 588
68. F. Durif, B. Debilly, M. Galitzky, D. Morand, F. Viallet, M. Borg, S. Thobois, E. Broussolle, and O. Rascol Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study Neurology 62 2004 381 388
69. N. Dygalo, G. Shishkina, T. Kalinina, A. Yudina, and E. Ovchinnikova Effect of repeated treatment with fluoxetine on tryptophan hydroxylase-2 gene expression in the rat brainstem Pharmacol. Biochem. Behav. 85 2006 220 227
70. Eating Disorders: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders National Institute for Health and Clinical Excellence: Guidance 2004 British Psychological Society (UK) Leicester (UK)
71. I.S. Ebenezer, and A. Surujbally The effects of 8-hydroxy-2-(di-n- propylamino)-tetralin (8-OH-DPAT) on food intake in non-deprived C57BL6 mice Eur. J. Pharmacol. 559 2007 184 188
72. M. Egeland, J. Warner-Schmidt, P. Greengard, and P. Svenningsson Co-expression of serotonin 5-HT1B and 5-HT4 receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum Neuropharmacology 61 2011 442 450
73. A. El Khoury, S.H.M. Gruber, A. Mørk, and A.A. Mathé Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 535 540
74. M. El Yacoubi, S. Bouali, D. Popa, L. Naudon, I. Leroux-Nicollet, M. Hamon, J. Costentin, J. Adrien, and J.-M. Vaugeois Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression Proc. Natl. Acad. Sci. 100 2003 6227 6232
75. G. Engberg A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade J. Neural Transm. 76 1989 91 98
76. K.L. Eskow, V. Gupta, S. Alam, J.Y. Park, and C. Bishop The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacol. Biochem. Behav. 87 2007 306 314
77. F. Fadda Tryptophan-free diets: a physiological tool to study brain serotonin function Physiology 15 2000 260 264
78. G.V. Fernández Macedo, M.L. Cladouchos, L. Sifonios, P.M. Cassanelli, and S. Wikinski Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm Psychopharmacology (Berl.) 225 2012 647 659
79. A.J. Ferrero, M. Cereseto, A. Reinés, C.D. Bonavita, L.L. Sifonios, M.C. Rubio, and S.I. Wikinski Chronic treatment with fluoxetine decreases seizure threshold in naïve but not in rats exposed to the learned helplessness paradigm: correlation with the hippocampal glutamate release Prog. Neuropsychopharmacol. Biol. Psychiatry 29 2005 678 686
80. C.F. Ferris, T. Stolberg, P. Kulkarni, M. Murugavel, R. Blanchard, D.C. Blanchard, M. Febo, M. Brevard, and N.G. Simon Imaging the neural circuitry and chemical control of aggressive motivation BMC Neurosci. 9 2008 111
81. M.B. Fontenot, M.W. Musso, R.M. McFatter, and G.M. Anderson Dose-finding study of fluoxetine and venlafaxine for the treatment of self-injurious and stereotypic behavior in rhesus macaques (Macaca mulatta) J. Am. Assoc. Lab. Animal Sci. JAALAS 48 2009 176 184
82. M.A. Fox, A.M. Andrews, J.R. Wendland, K.-P. Lesch, A. Holmes, and D.L. Murphy A pharmacological analysis of mice with a targeted disruption of the serotonin transporter Psychopharmacology (Berl.) 195 2007 147 166
83. V. Francardo, A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt, and M.A. Cenci Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease Neurobiol. Dis. 42 2011 327 340
84. H.M. Francis, N.J. Kraushaar, L.R. Hunt, and J.L. Cornish Serotonin 5-HT4 receptors in the nucleus accumbens are specifically involved in the appetite suppressant and not locomotor stimulant effects of MDMA ('ecstasy') Psychopharmacology (Berl.) 213 2010 355 363
85. M. Frank, and J.J. Braszko Moclobemide enhances aversively motivated learning and memory in rats Pol. J. Pharmacol. 51 1999 497 503
86. M. Franklin, I. Bermudez, H. Murck, N. Singewald, and S. Gaburro Sub-chronic dietary tryptophan depletion - an animal model of depression with improved face and good construct validity J. Psychiatr. Res. 46 2012 239 247
87. F. Fulceri, F. Biagioni, M. Ferrucci, G. Lazzeri, A. Bartalucci, V. Galli, S. Ruggieri, A. Paparelli, and F. Fornai Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons Brain Res. 1135 2007 219 229
88. R.W. Fuller The influence of fluoxetine on aggressive behavior Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 14 1996 77 81
89. K. Fuxe, S.O. Ogren, L.F. Agnati, G. Jonsson, and J.A. Gustafsson 5,7-Dihydroxytryptamine as a tool to study the functional role of central 5-hydroxytryptamine neurons Ann. N. Y. Acad. Sci. 305 1978 346 369
90. A.M. Gardier, A.C. Trillat, I. Malagié, D. David, M. Hascoët, M.C. Colombel, P. Jolliet, C. Jacquot, R. Hen, and M. Bourin Récepteurs 5-HT1B de la sérotonine et effets antidépresseurs des inhibiteurs de recapture sélectifs de la sérotonine: 5-HT1B receptors mediate the antidepressant effects of selective serotonin reuptake inhibitors Comptes Rendus Acad. Sci.-Ser. III-Sci. Vie 324 2001 433 441
91. P. Gaspar, C. Duyckaerts, C. Alvarez, F. Javoy-Agid, and B. Berger Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease Ann. Neurol. 30 1991 365 374
92. W.S. Gilmer, and W.T. McKinney Early experience and depressive disorders: human and non-human primate studies J. Affect. Disord. 75 2003 97 113
93. S.C. Godar, M. Bortolato, R. Frau, M. Dousti, K. Chen, and J.C. Shih Maladaptive defensive behaviours in monoamine oxidase A-deficient mice Int. J. Neuropsychopharmacol. 14 2010 1195 1207
94. N.T. Godart, M.F. Flament, Y. Lecrubier, and P. Jeammet Anxiety disorders in anorexia nervosa and bulimia nervosa: co-morbidity and chronology of appearance Eur. Psychiatry 15 2000 38 45
95. C.G. Goetz, P. Damier, C. Hicking, E. Laska, T. Müller, C.W. Olanow, O. Rascol, and H. Russ Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov. Disord. 22 2007 179 186
96. K.S. Gomes, E.F. de Carvalho-Netto, K.C.D. Monte, B. Acco, P.J. Nogueira, and R.L. Nunes-de-Souza Contrasting effects of acute and chronic treatment with imipramine and fluoxetine on inhibitory avoidance and escape responses in mice exposed to the elevated T-maze Brain Res. Bull. 78 2009 323 327
97. B. Gomez-Mancilla, and P.J. Bédard Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys Clin. Neuropharmacol. 16 1993 418 427
98. D. Grabli, K. McCairn, E.C. Hirsch, Y. Agid, J. Féger, C. François, and L. Tremblay Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study Brain J. Neurol. 127 2004 2039 2054
99. L. Grégoire, P. Samadi, J. Graham, P.J. Bédard, G.D. Bartoszyk, and T. Di Paolo Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys Park. Relat. Disord. 15 2009 445 452
100. G. Griebel, G. Perrault, and D.J. Sanger Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs Psychopharmacology (Berl.) 131 1997 180 186
101. R. Grondin, A. Hadj Tahar, V.D. Doan, P. Ladure, and P.J. Bédard Noradrenoceptor antagonism with idazoxan improves L-DOPA-induced dyskinesias in MPTP monkeys Naunyn. Schmiedeb. Arch. Pharmacol. 361 2000 181 186
102. J.-P. Guilloux, D.J.P. David, L. Xia, H.T. Nguyen, Q. Rainer, B.P. Guiard, C. Repérant, T. Deltheil, M. Toth, R. Hen, and A.M. Gardier Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments Neuropharmacology 61 2011 478 488
103. C.G. Gurtman, K.C. Morley, K.M. Li, G.E. Hunt, and I.S. McGregor Increased anxiety in rats after 3, 4-methylenedioxymethamphetamine: association with serotonin depletion Eur. J. Pharmacol. 446 2002 89 96
104. L. Gutknecht, C. Kriegebaum, J. Waider, A. Schmitt, and K.-P. Lesch Spatio-temporal expression of tryptophan hydroxylase isoforms in murine and human brain: convergent data from Tph2 knockout mice Eur. Neuropsychopharmacol. 19 2009 266 282
105. G. Hatzidimitriou, U.D. McCann, and G.A. Ricaurte Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery J. Neurosci. Off. J. Soc. Neurosci. 19 1999 5096 5107
106. B. Henry, S.H. Fox, D. Peggs, A.R. Crossman, and J.M. Brotchie The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease Mov. Disord. Off. J. Mov. Disord. Soc. 14 1999 744 753
107. J.D. Higley, and M. Linnoila Low central nervous system serotonergic activity is traitlike and correlates with impulsive behavior Ann. N. Y. Acad. Sci. 836 1997 39 56
108. A. Holmes, D. Murphy, and J. Crawley Reduced aggression in mice lacking the serotonin transporter Psychopharmacology (Berl.) 161 2002 160 167
109. A. Holmes, R.J. Yang, D.L. Murphy, and J.N. Crawley Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter Neuropsychopharmacology 27 2002 914 923
110. K. Holtkamp, K. Konrad, N. Kaiser, Y. Ploenes, N. Heussen, I. Grzella, and B. Herpertz-Dahlmann A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy J. Psychiatr. Res. 39 2005 303 310
111. P. Huot, T.H. Johnston, K.D. Lewis, J.B. Koprich, M.G. Reyes, S.H. Fox, M.J. Piggott, and J.M. Brotchie Characterization of 3,4- methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time J. Neurosci. Off. J. Soc. Neurosci. 31 2011 7190 7198
112. J.P. Huston, J. van den Brink, M. Komorowski, Y. Huq, and B. Topic Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior Neuroscience 210 2012 249 257
113. M.M. Iravani, M.J. Jackson, M. Kuoppamäki, L.A. Smith, and P. Jenner 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates J. Neurosci. Off. J. Soc. Neurosci. 23 2003 9107 9115
114. B.L. Jacobs, and E.C. Azmitia Structure and function of the brain serotonin system Physiol. Rev. 72 1992 165 229
115. J.W. Jahng, T.A. Houpt, T.H. Joh, and J.H. Son Differential expression of monoamine oxidase A, serotonin transporter, tyrosine hydroxylase and norepinephrine transporter mRNA by anorexia mutation and food deprivation Dev. Brain Res. 107 1998 241 246
116. H. Javelot, L. Weiner, R. Terramorsi, C. Rougeot, R. Lalonde, and M. Messaoudi Efficacy of chronic antidepressant treatments in a new model of extreme anxiety in rats Depress. Res. Treat. 2011 2011 531435
117. A. Jean, G. Conductier, C. Manrique, C. Bouras, P. Berta, R. Hen, Y. Charnay, J. Bockaert, and V. Compan Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens Proc. Natl. Acad. Sci. U. S. A. 104 2007 16335 16340
118. A. Jean, L. Laurent, J. Bockaert, Y. Charnay, N. Dusticier, A. Nieoullon, M. Barrot, R. Neve, and V. Compan The nucleus accumbens 5-HTR(4)-CART pathway ties anorexia to hyperactivity Transl. Psychiatry 2 2012 e203
119. K.A. Jennings Increased expression of the 5-HT transporter confers a low- anxiety phenotype linked to decreased 5-HT transmission J. Neurosci. 26 2006 8955 8964
120. E. Jéquier, W. Lovenberg, and A. Sjoerdsma Tryptophan hydroxylase inhibition: the mechanism by which p-chlorophenylalanine depletes rat brain serotonin Mol. Pharmacol. 3 1967 274 278
121. A. Jindal, R. Mahesh, and B. Kumar Anxiolytic-like effect of linezolid in experimental mouse models of anxiety Prog. Neuropsychopharmacol. Biol. Psychiatry 40 2013 47 53
122. N.J. Kalk, D.J. Nutt, and A.R. Lingford-Hughes The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies J. Psychopharmacol. (Oxf.) 25 2011 3 16
123. G.M. Karere, E.L. Kinnally, J.N. Sanchez, T.R. Famula, L.A. Lyons, and J.P. Capitanio What is an "Adverse" environment? Interactions of rearing experiences and MAOA genotype in rhesus monkeys Biol. Psychiatry 65 2009 770 777
124. R. Kavoussi, P. Armstead, and E. Coccaro The neurobiology of impulsive aggression Psychiatr. Clin. North Am. 20 1997 395 403
125. W.H. Kaye, T. Nagata, T.E. Weltzin, L.G. Hsu, M.S. Sokol, C. McConaha, K.H. Plotnicov, J. Weise, and D. Deep Double-blind placebo-controlled administration of fluoxetine in restricting-and restricting-purging-type anorexia nervosa Biol. Psychiatry 49 2001 644 652
126. S.J. Klenotich, M.P. Seiglie, M.S. McMurray, J.D. Roitman, D. Le Grange, P. Dugad, and S.C. Dulawa Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice Neuropsychopharmacology 37 2012 1620 1631
127. W.K. Kroeze, K. Kristiansen, and B.L. Roth Molecular biology of serotonin receptors structure and function at the molecular level Curr. Top. Med. Chem. 2 2002 507 528
128. W.-L. Kuan, J.-W. Zhao, and R.A. Barker The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram Psychopharmacology (Berl.) 197 2008 279 293
129. S. Lapmanee, N. Charoenphandhu, N. Krishnamra, and J. Charoenphandhu Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats Behav. Brain Res. 231 2012 20 28
130. F.B. Lima, M.L. Centeno, M.E. Costa, A.P. Reddy, J.L. Cameron, and C.L. Bethea Stress sensitive female macaques have decreased fifth Ewing variant (Fev) and serotonin-related gene expression that is not reversed by citalopram Neuroscience 164 2009 676 691
131. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem 112 2010 1465 1476
132. S.J. Line, C. Barkus, C. Coyle, K.A. Jennings, R.M. Deacon, K.P. Lesch, T. Sharp, and D.M. Bannerman Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice Eur. Neuropsychopharmacol. 21 2011 108 116
133. G. Lucas, V.V. Rymar, J. Du, O. Mnie-Filali, C. Bisgaard, S. Manta, L. Lambas-Senas, O. Wiborg, N. Haddjeri, G. Piñeyro, A.F. Sadikot, and G. Debonnel Serotonin4 (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action Neuron 55 2007 712 725
134. I. Lucki, A. Dalvi, and A.J. Mayorga Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice Psychopharmacology (Berl.) 155 2001 315 322
135. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
136. Y. Maki, T. Inoue, T. Izumi, I. Muraki, K. Ito, Y. Kitaichi, X. Li, and T. Koyama Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats Eur. J. Pharmacol. 406 2000 411 418
137. I. Malagié, A.C. Trillat, M. Bourin, C. Jacquot, R. Hen, and A.M. Gardier 5-HT1B autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex J. Neurochem. 76 2001 865 871
138. J.E. Malberg, A.J. Eisch, E.J. Nestler, and R.S. Duman Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus J. Neurosci. 20 2000 9104 9110
139. M.S. Man, J.W. Dalley, and A.C. Roberts Opposing effects of 5,7-DHT infusions into the orbitofrontal cortex and amygdala on flexible responding Cereb. Cortex 20 2009 1668 1675
140. J.M. Mancilla-Diaz, R.E. Escartin-Perez, V.E. Lopez-Alonso, B. Floran-Garduño, and J.B. Romano-Camacho Role of 5-HT Med. Sci. Monit. 11 2005 79
141. G.J. Mason Stereotypies: a critical review Animal Behav. 41 1991 1015 1037
142. M.A. Matar, H. Cohen, Z. Kaplan, and J. Zohar The effect of early poststressor intervention with sertraline on behavioral responses in an animal model of post-traumatic stress disorder Neuropsychopharmacology 31 2006 2610 2618
143. M. Mavridis, A.-D. Degryse, A.J. Lategan, M.R. Marien, and F.C. Colpaert Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease Neuroscience 41 1991 507 523
144. R. McQuade, and T. Sharp Release of cerebral 5-hydroxytryptamine evoked by electrical stimulation of the dorsal and median raphe nuclei: effect of a neurotoxic amphetamine Neuroscience 68 1995 1079 1088
145. R. McQuade, and T. Sharp Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis J. Neurochem. 69 1997 791 796
146. P.T. Mehlman, J.D. Higley, I. Faucher, A.A. Lilly, D.M. Taub, J. Vickers, S.J. Suomi, and M. Linnoila Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates Am. J. Psychiatry 151 1994 1485 1491
147. P.A. Melas, M. Rogdaki, A. Lennartsson, K. Björk, H. Qi, A. Witasp, M. Werme, G. Wegener, A.A. Mathé, P. Svenningsson, and C. Lavebratt Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression Int. J. Neuropsychopharmacol. 15 2011 669 679
148. G. Mengod, M.T. Vilaró, A. Raurich, J.F. López- Giménez, R. Cortés, and J.M. Palacios 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors Histochem. J. 28 1996 747 758
149. K.A. Michelsen, C. Schmitz, and H.W.M. Steinbusch The dorsal raphe nucleus - from silver stainings to a role in depression Brain Res. Rev. 55 2007 329 342
150. K.A. Miczek, E.W. Fish, J.F. de Bold, and R.M. de Almeida Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems Psychopharmacology (Berl.) 163 2002 434 458
151. E. Mikrouli, G. Wörtwein, R. Soylu, A.A. Mathé, and Å. Petersén Increased numbers of orexin/hypocretin neurons in a genetic rat depression model Neuropeptides 45 2011 401 406
152. C. Moret, and M. Briley Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain Eur. J. Pharmacol. 295 1996 189 197
153. N. Morin, V.A. Jourdain, and T. Di Paolo Modeling dyskinesia in animal models of Parkinson disease Exp. Neurol. Jan 27 2013
154. K.C. Morley, J.E. Gallate, G.E. Hunt, P.E. Mallet, and I.S. McGregor Increased anxiety and impaired memory in rats 3 months after administration of 3, 4-methylenedioxymethamphetamine ("ecstasy") Eur. J. Pharmacol. 433 2001 91 99
155. A. Muñoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Björklund, E. Bezard, and M. Carta Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain J. Neurol. 131 2008 3380 3394
156. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdère Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease Neurobiol. Dis. 38 1 2010 136 143
157. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat. Neurosci. 13 2010 1161 1169
158. A.P. Nicholas, K. Buck, and B. Ferger Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity Neurosci. Lett. 443 2008 204 208
159. D.E. Nichols, and C.D. Nichols Serotonin receptors Chem. Rev. 108 2008 1614 1641
160. M.A. Novak, J.H. Kinsey, M.J. Jorgensen, and T.J. Hazen Effects of puzzle feeders on pathological behavior in individually housed rhesus monkeys Am. J. Primatol. 46 3 1998 213 227
161. C.W. Olanow, P. Damier, C.G. Goetz, T. Mueller, J. Nutt, O. Rascol, A. Serbanescu, F. Deckers, and H. Russ Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) Clin. Neuropharmacol. 27 2004 58 62
162. B. Olivier, and J. Mos Rodent models of aggressive behavior and serotonergic drugs Prog. Neuropsychopharmacol. Biol. Psychiatry 16 1992 847 870
163. J.D.A. Olivier, T. Blom, T. Arentsen, and J.R. Homberg The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2010 1400 1408
164. G. Ossowska, B. Klenk-Majewska, Z. Danilczuk, A. Wróbel, and I. Zebrowska-Lupina Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors Pol. J. Pharmacol. 51 1999 391 397
165. M.J. Owens, D.L. Knight, and C.B. Nemeroff Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine Biol. Psychiatry 50 2001 345 350
166. G.I. Papakostas, and M. Fava A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Can. J. Psychiatry Rev. Can. Psychiatr. 51 2006 783 790
167. C.L. Parks, P.S. Robinson, E. Sibille, T. Shenk, and M. Toth Increased anxiety of mice lacking the serotonin1A receptor Proc. Natl. Acad. Sci. 95 1998 10734 10739
168. C. Pifl, O. Hornykiewicz, J. Blesa, R. Adánez, C. Cavada, and J.A. Obeso Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of Parkinsonism J. Neurochem 125 2013 657 662
169. S. Pini, X.F. Amador, L. Dell'Osso, N.B. Rossi, P. Cassano, M. Savino, and G.B. Cassano Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide Int. Clin. Psychopharmacol. 18 2003 15 21
170. R. Pohl, V.K. Yeragani, R. Balon, and H. Lycaki The jitteriness syndrome in panic disorder patients treated with antidepressants J. Clin. Psychiatry 49 1988 100 104
171. M. Politis, W.H. Oertel, K. Wu, N.P. Quinn, O. Pogarell, D.J. Brooks, A. Bjorklund, O. Lindvall, and P. Piccini Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio Mov. Disord. Off. J. Mov. Disord. Soc. 26 2011 1997 2003
172. S.C. Poltronieri, H. Zangrossi, M. de Barros Viana, and others Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze Behav. Brain Res. 147 2003 185 192
173. N.K. Popova, G.B. Vishnivetskaya, E.A. Ivanova, J.A. Skrinskaya, and I. Seif Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline Pharmacol. Biochem. Behav. 67 2000 719 727
174. J. Prasko, C. Dockery, J. Horácek, P. Houbová, J. Kosová, J. Klaschka, B. Pasková, H. Praskova, D. Seifertová, R. Záleský, and C. Höschl Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up Neuro Endocrinol. Lett. 27 2006 473 481
175. W.E. Pratt, K. Blackstone, M.E. Connolly, and M.J. Skelly Selective serotonin receptor stimulation of the medial nucleus accumbens causes differential effects on food intake and locomotion Behav. Neurosci. 123 2009 1046 1057
176. A. Pringle, K.A. Jennings, S. Line, D.M. Bannerman, S. Higgs, and T. Sharp Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine Psychopharmacology (Berl.) 200 2008 291 300
177. M.J. Raleigh, M.T. McGuire, G.L. Brammer, D.B. Pollack, and A. Yuwiler Serotonergic mechanisms promote dominance acquisition in adult male vervet monkeys Brain Res. 559 1991 181 190
178. S. Ravinder, A.G. Pillai, and S. Chattarji Cellular correlates of enhanced anxiety caused by acute treatment with the selective serotonin reuptake inhibitor fluoxetine in rats Front. Behav. Neurosci. 5 2011 88
179. J.W. Richardson-Jones, C.P. Craige, T.H. Nguyen, H.F. Kung, A.M. Gardier, A. Dranovsky, D.J. David, B.P. Guiard, S.G. Beck, R. Hen, and E.D. Leonardo Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety J. Neurosci. 31 2011 6008 6018
180. T.W. Robbins, C.M. Gillan, D.G. Smith, S. de Wit, and K.D. Ersche Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry Trends Cogn. Sci. 16 1 2012 81 91
181. A. Routtenberg, and A.W. Kuznesof Self-starvation of rats living in activity wheels on a restricted feeding schedule J. Comp. Physiol. Psychol. 64 1967 414 421
182. D. Rylander, M. Parent, S.S. O'Sullivan, S. Dovero, A.J. Lees, E. Bezard, L. Descarries, and M.A. Cenci Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann. Neurol. 68 5 2010 619 628
183. L. Santarelli Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805 809
184. F. Saudou, D.A. Amara, A. Dierich, M. LeMeur, S. Ramboz, L. Segu, M.-C. Buhot, and R. Hen Enhanced aggressive behavior in mice lacking 5-HT1B receptor Science 265 1994 1875 1878
185. K.V. Savelieva, S. Zhao, V.M. Pogorelov, I. Rajan, Q. Yang, E. Cullinan, and T.H. Lanthorn Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants PLoS One 3 2008 e3301
186. A.L. Scott, M. Bortolato, K. Chen, and J.C. Shih Novel monoamine oxidase A knock out mice with human-like spontaneous mutation Neuroreport 19 2008 739 743
187. V. Sgambato-Faure, M. Beaudoin-Gobert, J. Epinat, G. Jarre, S. Neumane, and L. Tremblay Characterization and behavioural impact of a serotonergic lesion in MPTP-intoxicated monkeys Mov. Disord. 27 Suppl. 1 2012 853
188. V. Sgambato-Faure, V. Buggia, F. Gilbert, D. Lévesque, A.-L. Benabid, and F. Berger Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats J. Neuropathol. Exp. Neurol. 64 2005 936 947
189. Y. Shen, T.J. Connor, Y. Nolan, J.P. Kelly, and B.E. Leonard Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat Life Sci. 65 1999 1773 1786
190. N. Shimizu, T. Hori, C. Ogino, T. Kawanishi, and Y. Hayashi The 5-HT1A receptor agonist, 8-OH-DPAT, attenuates stress-induced anorexia in conjunction with the suppression of hypothalamic serotonin release in rats Brain Res. 887 2000 178 182
191. C.A. Shively, K. Laber-Laird, and R.F. Anton Behavior and physiology of social stress and depression in female cynomolgus monkeys Biol. Psychiatry 41 1997 871 882
192. C.A. Shively, T.C. Register, D.P. Friedman, T.M. Morgan, J. Thompson, and T. Lanier Social stress-associated depression in adult female cynomolgus monkeys (Macaca fascicularis) Biol. Psychol. 69 2005 67 84
193. B. Shopsin, E. Friedman, and S. Gershon Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients Arch. Gen. Psychiatry 33 1976 811 819
194. A. Sjoerdsma, T.E. Smith, T.D. Stevenson, and S. Udenfriend Metabolism of 5-hydroxytryptamine (serotonin) by monoamine oxidase Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. N. Y. N 89 1955 36 38
195. J.G. Soares, J.R.L.P. Cavalcanti, F.G. Oliveira, A.L.B. Pontes, T.B. Sousa, L.M. Freitas, J.S. Cavalcante, E.S. Nascimento, J.C. Cavalcante, and M.S.M.O. Costa Nuclear organization of the serotonergic system in the brain of the rock cavy (Kerodon rupestris) J. Chem. Neuroanat. 43 2012 112 119
196. P. Stark, and C.D. Hardison A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder J. Clin. Psychiatry 46 1985 53 58
197. D.M. Stone, M. Johnson, G.R. Hanson, and J.W. Gibb Role of endogenous dopamine in the central serotonergic deficits induced by 3,4- methylenedioxymethamphetamine J. Pharmacol. Exp. Ther. 247 1988 79 87
198. P. Svenningsson Alterations in 5-HT1B receptor function by p11 in depression-like states Science 311 2006 77 80
199. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 3 1999 631 634
200. K. Taravosh-Lahn, C. Bastida, and Y. Delville Differential responsiveness to fluoxetine during puberty Behav. Neurosci. 120 2006 1084 1092
201. E. Tatarczyńska, A. Kłodzińska, K. Stachowicz, and E. Chojnacka-Wójcik Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test Eur. J. Pharmacol. 487 2004 133 142
202. R.C. Teixeira, H. Zangrossi, and F.G. Graeff Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety Pharmacol. Biochem. Behav. 65 2000 571 576
203. Y. Temel, L.J. Boothman, A. Blokland, P.J. Magill, H.W. Steinbusch, V. Visser-Vandewalle, and T. Sharp Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus Proc. Natl. Acad. Sci. 104 2007 17087 17092
204. M.R. Thompson, K.M. Li, K.J. Clemens, C.G. Gurtman, G.E. Hunt, J.L. Cornish, and I.S. McGregor Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ("Ecstasy") in rats Neuropsychopharmacology 29 2003 694 704
205. R.P. Vertes A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat J. Comp. Neurol. 313 1991 643 668
206. M.A. Vicente, and H. Zangrossi Involvement of 5-HT2C and 5-HT1A receptors of the basolateral nucleus of the amygdala in the anxiolytic effect of chronic antidepressant treatment Neuropharmacology 79 2013 127 135
207. J.G. Villarinho, R. Fachinetto, F. de V. Pinheiro, G. da S. Sant'Anna, P. Machado, P.A. Dombrowski, C. da Cunha, D. de A. Cabrini, M.A.P. Martins, H.G. Bonacorso, N. Zanatta, M.A. Rubin, and J. Ferreira Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice Prog. Neuropsychopharmacol. Biol. Psychiatry 39 2012 31 39
208. N. Visanji, S. Fox, T. Johnston, M. Millan, and J. Brotchie alpha1-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaques J. Pharmacol. Exp. Ther. 328 2009 276 283
209. G.B. Vishnivetskaya, J.A. Skrinskaya, I. Seif, and N.K. Popova Effect of MAO A deficiency on different kinds of aggression and social investigation in mice Aggress. Behav. 33 2007 1 6
210. J.P. Voigt, F. Kienzle, R. Sohr, A. Rex, and H. Fink Feeding and 8-OH-DPAT-related release of serotonin in the rat lateral hypothalamus Pharmacol. Biochem. Behav. 65 2000 183 189
211. C. Von Meyenburg, W. Langhans, and B.J. Hrupka Evidence that the anorexia induced by lipopolysaccharide is mediated by the 5-HT2C subreceptor Pharmacol. Biochem. Behav. 74 2003 505 512
212. B.T. Walsh, C.G. Fairburn, D. Mickley, R. Sysko, and M.K. Parides Treatment of bulimia nervosa in a primary care setting Am. J. Psychiatry 161 2004 556 561
213. D.J. Walther, and M. Bader A unique central tryptophan hydroxylase isoform Biochem. Pharmacol. 66 2003 1673 1680
214. W. Wang, Y. Liu, H. Zheng, H.N. Wang, X. Jin, Y.C. Chen, L.N. Zheng, X.X. Luo, and Q.R. Tan A modified single-prolonged stress model for post-traumatic stress disorder Neurosci. Lett. 441 2008 237 241
215. J.L. Warner-Schmidt, M. Flajolet, A. Maller, E.Y. Chen, H. Qi, P. Svenningsson, and P. Greengard Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation J. Neurosci. 29 2009 1937 1946
216. K.V. Weissheimer, S.M. Herod, J.L. Cameron, and C.L. Bethea Interactions of corticotropin-releasing factor, urocortin and citalopram in a primate model of stress-induced amenorrhea Neuroendocrinology 92 2010 224 234
217. G.C. Westergaard, S.J. Suomi, T.J. Chavanne, L. Houser, A. Hurley, A. Cleveland, P.J. Snoy, and J.D. Higley Physiological correlates of aggression and impulsivity in free-ranging female primates Neuropsychopharmacology 28 2003 1045 1055
218. G.C. Westergaard, S.J. Suomi, J.D. Higley, and P.T. Mehlman CSF 5-HIAA and aggression in female macaque monkeys: species and interindividual differences Psychopharmacology (Berl.) 146 1999 440 446
219. S.L. Willard, and C.A. Shively Modeling depression in adult female cynomolgus monkeys (Macaca fascicularis) Am. J. Primatol. 74 2012 528 542
220. Y. Worbe, N. Baup, D. Grabli, M. Chaigneau, S. Mounayar, K. McCairn, J. Féger, and L. Tremblay Behavioral and movement disorders induced by local inhibitory dysfunction in primate striatum Cereb. Cortex 19 2009 1844 1856
221. R. Yadav, M. Suri, R. Mathur, and S. Jain Effect of procainization of ventromedial nucleus of hypothalamus on the feeding behavior of rats J. Clin. Biochem. Nutr. 44 2009 247 252
222. R. Yirmiya Endotoxin produces a depressive-like episode in rats Brain Res. 711 1996 163 174
223. R. Yirmiya, Y. Pollak, O. Barak, R. Avitsur, H. Ovadia, M. Bette, E. Weihe, and J. Weidenfeld Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents Neuropsychopharmacology 24 2001 531 544
224. S.N. Young, S.E. Smith, R.O. Pihl, and F.R. Ervin Tryptophan depletion causes a rapid lowering of mood in normal males Psychopharmacology (Berl.) 87 1985 173 177
225. X. Zhuang, C. Gross, L. Santarelli, V. Compan, A.C. Trillat, and R. Hen Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 21 1999 52S 60S